Featured News
AIM Blog
Recognizing AIM’s August Advocate of the Month: Vinitia Strong-McDonald
Each month, we’re featuring an advocate who engages with policymakers to ensure priorities that improve the lives of people impacted by Alzheimer’s and all other dementia remain top-of-mind in Congres...
All News
Press Release
Critical Legislation to Renew National Commitment to Fighting Alzheimer’s Reintroduced in Congress
NAPA Reauthorization Act and Alzheimer’s Accountability and Investment Act Washington, D.C., January 31, 2023 — The Alzheimer’s Association and the...
Press Release
Alzheimer’s Association Welcomes U.S. FDA Approval of Lecanemab
Association Renews Urgent Call for CMS to Cover FDA-Approved Alzheimer’s Treatments CHICAGO, January 6, 2023 — The Alzheimer’s Association enthusiastically...
Press Release
Critical Alzheimer’s and Dementia Priorities Signed Into Law
Washington, D.C., December 29, 2022 – The Alzheimer’s Association and the Alzheimer’s Impact Movement (AIM) commend the passage of the...
Press Release
Congress Prioritizes Addressing Alzheimer’s and Dementia
Key provisions of the ENACT Act, language to strengthen FDA accelerated approval pathway, a $226 million increase for Alzheimer’s and...
Press Release
Alzheimer’s Association Calls on CMS to Reverse Its Decision to Severely Limit Access to FDA-Approved Alzheimer’s Disease Treatments
Association Files Formal Request for Reconsideration of National Coverage Determination for Monoclonal Antibodies Directed Against Amyloid for the Treatment of...
Press Release
Alzheimer’s Association Statement On Gantenerumab Phase 3 Topline Data Release
Chicago, November 14, 2022 — The Alzheimer’s Association is disappointed by the topline Phase 3 data reported today by Genentech...